Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys

Clinical and Vaccine Immunology

Volumn 22, Issue 5, 2015, Pages 516-525

  Liu, Ge ^a   Song, Langzhou ^a   Beasley, David W C ^b   Putnak, Robert ^c   Parent, Jason ^a   Misczak, John ^a   Li, Hong ^a   Reiserova, Lucia ^a   Liu, Xiangyu ^a   Tian, Haijun ^a   Liu, Wenzhe ^a   Labonte, Darlene ^a   Duan, Lihua ^a   Kim, Youngsun ^a   Travalent, Linda ^a   Wigington, Devin ^a   Weaver, Bruce ^a   Tussey, Lynda ^a  

^a VaxInnate Corporation   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; FLAGELLIN; FLAGELLIN VIRUS ENVELOPE PROTEIN FUSION PROTEIN VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; CYTOKINE; LIVE VACCINE; SUBUNIT VACCINE; TOLL LIKE RECEPTOR 5; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENGUE; DRUG EFFICACY; DRUG SCREENING; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RHESUS MONKEY; VIREMIA; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; DENGUE VIRUS; DISEASE MODEL; GENETICS; IMMUNOLOGY; SERODIAGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOKINES; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; FLAGELLIN; INJECTIONS, SUBCUTANEOUS; MACACA MULATTA; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; TOLL-LIKE RECEPTOR 5; VACCINES, ATTENUATED; VACCINES, SUBUNIT; VIREMIA;

EID: 84929092600     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00770-14     Document Type: Article

References (46)

1. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. 2011. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29:7242-7250. http://dx.doi.org/10.1016/j.vaccine.2011.07.023.
2. Osorio JE, Huang CYH, Kinney RM, Stinchcomb DT. 2011. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29:7251-7260. http://dx.doi.org/10.1016/j.vaccine.2011.07.020.
3. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. 2011. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29:7229-7241. http://dx.doi.org/10.1016/j.vaccine.2011.06.094.
4. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, Van Der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, CYD14 Study Group. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358-1365. http://dx.doi.org/10.1016/S0140-6736 (14) 61060-6.
5. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736 (12) 61428-7.
6. Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, Sadoff JC, Eckels KH. 1996. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protectionin mice and rhesus monkeys. JInfect Dis 174:1176-1184. http://dx.doi.org/10.1093/infdis/174.6.1176.
7. Danko JR, Beckett CG, Porter KR. 2011. Development of dengue DNA vaccines. Vaccine 29:7261-7266. http://dx.doi.org/10.1016/j.vaccine.2011.07.019.
8. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. 2011. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29:7267-7275. http://dx.doi.org/10.1016/j.vaccine.2011.07.021.
9. Weaver SC, Barrett AD. 2004. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat Rev Microbiol 2:789-801. http://dx.doi.org/10.1038/nrmicro1006.
10. Murphy BR, Whitehead SS. 2011. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29:587-619. http://dx.doi.org/10.1146/annurev-immunol-031210-101315.
11. Roehrig JT, Bolin RA, Kelly RG. 1998. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246:317-328. http://dx.doi.org/10.1006/viro.1998.9200.
12. Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, Chanock R, Moss B, Lai CJ. 2000. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoproteinof dengue type2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18:3113-3122. http://dx.doi.org/10.1016/S0264-410X (00) 00121-3.
13. Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319. http://dx.doi.org/10.1038/nature02165.
14. Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82:8828-8837. http://dx.doi.org/10.1128/JVI.00606-08.
15. Crill WD, Roehrig JT. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75:7769-7773. http://dx.doi.org/10.1128/JVI.75.16.7769-7773.2001.
16. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81:12816-12826. http://dx.doi.org/10.1128/JVI.00432-07.
17. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84:9227-9239. http://dx.doi.org/10.1128/JVI.01087-10.
18. Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G. 2010. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 9:137-147. http://dx.doi.org/10.1586/erv. 09.139.
19. Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, Jacobs A, Liu G, Huang Y, Desai P, Maksymiuk G, Takahashi V, Umlauf S, Reiserova L, Bell R, Li H, Zhang Y, McDonald WF, Powell TJ, Tussey L. 2008. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 3:e2257. http://dx.doi.org/10.1371/journal.pone.0002257.
20. Song L, Zhang Y, Yun NE, Poussard AL, Smith JN, Smith JK, Borisevich V, Linde JJ, Zacks MA, Li H, Kavita U, Reiserova L, Liu X, Dumuren K, Balasubramanian B, Weaver B, Parent J, Umlauf S, Liu G, Huleatt J, Tussey L, Paessler S. 2009. Superior efficacy of a recombinant flagellin: H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 27:5875-5884. http://dx.doi.org/10.1016/j.vaccine.2009.07.060.
21. Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y, Li H, Hou F, Liu X, Parent J, Umlauf S, Shaw A, Tussey L. 2011. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS One 6:e20928. http://dx.doi.org/10.1371/journal.pone.0020928.
22. Liu G, Song L, Reiserova L, Trivedi U, Li H, Liu X, Noah D, Hou F, Weaver B, Tussey L. 2012. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine 30:6833-6838. http://dx.doi.org/10.1016/j.vaccine.2012.09.013.
23. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A. 2011. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2. HA1 SI). Vaccine 29:4897-4902. http://dx.doi.org/10.1016/j.vaccine.2011.05.001.
24. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, Liu G, Kavita U, Song L, Dark I, Shaw A. 2010. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28:8268-8274. http://dx.doi.org/10.1016/j.vaccine.2010.10.009.
25. Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A. 2012. Development of VAX128, a recombinant hemagglutinin (HA) influenzaflagellin fusion vaccine with improved safety and immune response. Vaccine 30:5761-5769. http://dx.doi.org/10.1016/j.vaccine.2012.06.086.
26. McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ. 2007. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 195:1607-1617. http://dx.doi.org/10.1086/517613.
27. Song L, Liu G, Umlauf S, Liu X, Li H, Tian H, Reiserova L, Hou F, Bell R, Tussey L. 2014. A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of influenza B globular head vaccines. Vaccine 32:4317-4323. http://dx.doi.org/10.1016/j.vaccine.2014.06.013.
28. Messer WB, Yount B, Hacker KE, Donaldson EF, Huynh JP, De Silva AM, Baric RS. 2012. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl Trop Dis 6:e1486. http://dx.doi.org/10.1371/journal.pntd.0001486.
29. Roehrig JT, Hombach J, Barrett AD. 2008. Guidelines for plaquereduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21:123-132. http://dx.doi.org/10.1089/vim.2008.0007.
30. National Research Council. 2011. Guide for the care and use oflaboratory animals, 8th ed. National Academies Press, Washington, DC.
31. Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R. 2006. Characterization of antibody responses to combinations of a dengue virus type2 DNA vaccine and two dengue virus type2 protein vaccinesinrhesus macaques. JVirol 80:9577-9585. http://dx.doi.org/10.1128/JVI.00284-06.
32. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen N, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, De Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283. http://dx.doi.org/10.1016/j.chom.2010.08.007.
33. Messer WB, De Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE, Jr, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, De Silva AM, Baric RS. 2014. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A 111:1939-1944. http://dx.doi.org/10.1073/pnas.1317350111.
34. White LJ, Sariol CA, Mattocks MD, Wahala MPB, Yingsiwaphat V, Collier ML, Whitley J, Mikkelsen R, Rodriguez IV, Martinez MI, De Silva A, Johnston RE. 2013. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J Virol 87:3409-3424. http://dx.doi.org/10.1128/JVI.02298-12.
35. Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, Lopez C, Martinez R, Castro J, Santana E, Hermida L, Guillen G, Guzman MG. 2008. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 80:194-199. http://dx.doi.org/10.1016/j.antiviral.2008.06.005.
36. Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra BL, Martinez R, Rodriguez R, Zulueta A, Perez AB, Lazo L, Rosario D, Guillen G, Guzman MG. 2006. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24:3165-3171. http://dx.doi.org/10.1016/j.vaccine.2006.01.036.
37. Medzhitov R, Janeway C, Jr. 2000. Innate immunity. N Engl J Med 343:338-344. http://dx.doi.org/10.1056/NEJM200008033430506.
38. Janeway CA, Jr, Medzhitov R. 2002. Innate immune recognition. Annu Rev Immunol 20:197-216. http://dx.doi.org/10.1146/annurev. immunol.20.083001.084359.
39. Blander JM, Medzhitov R. 2004. Regulation of phagosome maturation by signals from Toll-like receptors. Science 304:1014-1018. http://dx.doi.org/10.1126/science.1096158.
40. Blander JM, Medzhitov R. 2006. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440:808-812. http://dx.doi.org/10.1038/nature04596.
41. De Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, De Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5:e1188. http://dx.doi.org/10.1371/journal.pntd.0001188.
42. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, De Silva AM. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103-113. http://dx.doi.org/10.1016/j.virol.2009.06.037.
43. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T. 2010. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28:2705-2715. http://dx.doi.org/10.1016/j.vaccine.2010.01.022.
44. Putnak JR, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA, Seriwatana J, Cayphas S, Garcon N, Gheysen D, Kanesa-Thasan N, McDonell M, Humphreys T, Eckels KH, Prieels JP, Innis BL. 2005. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23:4442-4452. http://dx.doi.org/10.1016/j.vaccine.2005.03.042.
45. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinsky A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, Grimes JM, Tsai W, Lai C, Wang W, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. 2015. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170-177. http://dx.doi.org/10.1038/ni.3058.
46. Manoff S, Sausser M, Finn T, Russell A, Tannenbaum B, Radley D, Hyatt D, Robberts C, Bett A, Martin J, Coller B. 2014. Phase I clinical testing of recombinant subunit vaccine for dengue. Am J Trop Med Hyg 91(Suppl 1):173-174.